Jun 29 2010
DARA was an Early Investor in SurgiVision and Presently Owns 1.6 Million Shares and Warrants to Purchase an Additional 405,000 Shares
DARA BioSciences, Inc. (Nasdaq:DARA), announced today that SurgiVision, Inc., a privately held company of which DARA owns 1,613,258 shares and warrants to purchase an additional 405,000 shares, has received 510(k) clearance from the Food and Drug Administration (FDA) to market their ClearPoint system in the United States for general neurological interventional procedures.
For more information regarding the Amendment go to http://www.sec.gov/edgar/searchedgar/companysearch.html
The ClearPoint system is designed to allow minimally invasive procedures in the brain to be performed in an existing MRI suite. The ClearPoint system is an integrated system of reusable components, disposable components and intuitive, menu-driven software, which is referred to as SurgiVision's marketed products. Utilization of the ClearPoint system allows a physician to see and select a neurological target, aim the targeting device and watch as the surgical instrument is advanced to the target, significantly reducing the time and complexity of the interventional procedure.